Furosemide Shortage: What Providers and Prescribers Need to Know in 2026

Furosemide is a cornerstone of diuretic therapy in cardiology, nephrology, and internal medicine. With more than 19 million prescriptions in 2023 and widespread use in inpatient settings, supply disruptions—even partial ones—have significant clinical consequences. This article provides a current clinical overview of furosemide availability in 2026 and practical guidance for prescribers managing patients during shortage conditions.

Current Supply Landscape: 2026 Update

As of early 2026, the furosemide supply picture is split:

Oral tablets (20 mg, 40 mg, 80 mg): Not on the FDA's active shortage list. Manufactured by multiple generic producers; retail availability is generally adequate. Occasional localized stockouts occur at individual pharmacies but are not systemic.

Oral solution (10 mg/mL): Available but less commonly stocked at retail pharmacies. Specialty pharmacies and compounding pharmacies may be required for some patients.

Injectable furosemide (10 mg/mL vials): Active shortage conditions as of early 2026. Manufacturers including Hikma have reported backorder on 10 mL and 50 mL vials. Short-dated stock has been available, but forward supply remains uncertain. Hospital pharmacists are actively managing allocation.

Furoscix (subcutaneous kit): Available through specialty pharmacies. May be a viable outpatient option for appropriate heart failure patients who previously required IV access for acute decompensation management.

Clinical Implications of Injectable Furosemide Shortage

IV furosemide is essential in several high-acuity scenarios: acute decompensated heart failure (ADHF), acute pulmonary edema, acute kidney injury with fluid overload, and severe hypercalcemia. When IV supply is constrained, institutions must develop systematic substitution protocols to ensure safe, effective care.

Key risks during shortage-related substitution include:

Medication errors related to dose conversion (particularly furosemide-to-bumetanide conversions)

Delayed diuresis in patients receiving insufficient therapeutic substitution

Patient confusion when transitioning between agents at different points of care (ER, ICU, floor, outpatient)

Therapeutic Substitution: Loop Diuretic Dose Conversion Guide

When IV furosemide is unavailable, the following approximate equivalencies can guide substitution. These are starting points—titrate based on clinical response, renal function, and volume status:

Furosemide 40 mg IV ≈ Bumetanide 1 mg IV (40:1 ratio — bumetanide is 40x more potent)

Furosemide 40 mg IV ≈ Torsemide 20 mg IV (2:1 ratio — frequently used for ADHF)

Furosemide 40 mg IV ≈ Furosemide 80 mg PO (IV bioavailability is approximately 2x oral)

Critical safety note on bumetanide:

The 40:1 potency ratio between furosemide and bumetanide has been associated with serious medication errors and patient harm. When substituting bumetanide, ensure: (1) the order is entered by a clinician familiar with the conversion, (2) pharmacy double-checks the dose, and (3) nursing is alerted to the potency difference. ISMP has highlighted furosemide-to-bumetanide conversions as a high-alert substitution.

Clinical Considerations for Specific Patient Populations

Acute Decompensated Heart Failure (ADHF): For patients not previously on diuretics, start IV at 20–40 mg and titrate. For those on chronic oral furosemide, initiate IV at a dose equivalent to or greater than total daily oral dose per ACC/AHA guidelines. IV torsemide is an evidence-supported substitution.

Chronic Kidney Disease (CKD): Patients with eGFR < 30 mL/min often require higher furosemide doses due to reduced tubular secretion. Torsemide may have more consistent absorption in these patients. Monitor BUN, creatinine, and electrolytes closely.

Liver Cirrhosis with Ascites: Furosemide is typically used in combination with spironolactone (standard ratio 40:100 mg). Monitor for hepatic encephalopathy. Electrolyte correction prior to initiation is essential.

Sulfa Allergy: Recent evidence suggests cross-reactivity between antibiotic sulfonamides and furosemide (a non-antibiotic sulfonamide) is unlikely. However, in patients with documented severe sulfa hypersensitivity, ethacrynic acid (Edecrin) remains the only loop diuretic without a sulfonamide structure.

Outpatient Management: Helping Patients Find Furosemide

For outpatient prescribers, patient medication access is a growing part of clinical practice. When patients call reporting that their pharmacy is out of furosemide, consider directing them to medfinder for providers. medfinder contacts pharmacies near the patient to find which ones can fill the prescription—saving clinical staff time and getting the patient their medication faster.

Monitoring Parameters During Furosemide Therapy (and Substitution)

Serum electrolytes (Na, K, Cl, Mg, Ca) — hypokalemia and hypomagnesemia are common and can precipitate arrhythmias

Serum creatinine and BUN — monitor for pre-renal azotemia from over-diuresis

Uric acid — furosemide and other loop diuretics can precipitate gout via hyperuricemia

Blood pressure and orthostatic measurements — especially in elderly patients

Daily weights in heart failure patients — a 2+ lb overnight gain warrants reassessment

Hearing — ototoxicity risk increases with high doses, rapid IV administration, and concurrent aminoglycoside use

See also: How to help your patients find furosemide in stock: a provider's guide.